荣昌生物眼科新药上市遇阻

中国经营报07-30 10:12

中经记者陈婷深圳报道　　7月28日，国家药监局公示药品通知件送达信息，涉及7款药品，其中包括荣昌生物（688331.SH/9995.HK）申报的伊立芙普α眼内注射液（RC28-E，受理号：CXSS2500103）。据悉，申请人收到“药品通知件”通常意味着药品的注册申请未获批准或被主动撤回。国家药监局公示2026年7月28日药品通知件送达信息来源：国家药监局官网　　RC28-E是荣昌生物自主研发的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2655849376?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-30 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655849376","market":"hk","top_or_hot":-1,"title":"荣昌生物眼科新药上市遇阻","media":"中国经营报","content":"<div>\n<p>中经记者陈婷深圳报道　　7月28日，国家药监局公示药品通知件送达信息，涉及7款药品，其中包括荣昌生物（688331.SH/9995.HK）申报的伊立芙普α眼内注射液（RC28-E，受理号：CXSS2500103）。据悉，申请人收到“药品通知件”通常意味着药品的注册申请未获批准或被主动撤回。 国家药监局公示2026年7月28日药品通知件送达信息来源：国家药监局官网　　RC28-E是荣昌生物自主研发的...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607303826261788.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>荣昌生物眼科新药上市遇阻</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n荣昌生物眼科新药上市遇阻\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-30 10:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202607303826261788.html><strong>中国经营报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中经记者陈婷深圳报道　　7月28日，国家药监局公示药品通知件送达信息，涉及7款药品，其中包括荣昌生物（688331.SH/9995.HK）申报的伊立芙普α眼内注射液（RC28-E，受理号：CXSS2500103）。据悉，申请人收到“药品通知件”通常意味着药品的注册申请未获批准或被主动撤回。 国家药监局公示2026年7月28日药品通知件送达信息来源：国家药监局官网　　RC28-E是荣昌生物自主研发的...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607303826261788.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://finance.eastmoney.com/a/202607303826261788.html","article_id":"2655849376","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303826261788.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655849376","pubTimestamp":1785377536,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"中经记者陈婷深圳报道7月28日，国家药监局公示药品通知件送达信息，涉及7款药品，其中包括荣昌生物（688331.SH/9995.HK）申报的伊立芙普α眼内注射液（RC28-E，受理号：CXSS2500103）。据悉，申请人收到“药品通知件”通常意味着药品的注册申请未获批准或被主动撤回。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688331":"荣昌生物","BK0239":"医药制造","09995":"荣昌生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IPOS":"Renaissance International IPO ETF","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK1161":"生物科技","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK1574":"生物医药B类股","BK1583":"高瓴概念"},"translate_title":"Rongchang Biological's new ophthalmic drug listing encounters obstacles","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1.5,"09995":1.5,"IPOS":1.5},"content_text":"中经记者陈婷深圳报道　　7月28日，国家药监局公示药品通知件送达信息，涉及7款药品，其中包括荣昌生物（688331.SH/9995.HK）申报的伊立芙普α眼内注射液（RC28-E，受理号：CXSS2500103）。据悉，申请人收到“药品通知件”通常意味着药品的注册申请未获批准或被主动撤回。 国家药监局公示2026年7月28日药品通知件送达信息来源：国家药监局官网　　RC28-E是荣昌生物自主研发的针对眼部新生血管性疾病的VEGF/FGF双靶标融合蛋白药物。去年9月，荣昌生物宣布RC28-E用于治疗糖尿病性黄斑水肿（DME）患者的新药上市申请获国家药监局药品审评中心受理。该上市申请是基于一项多中心、随机、双盲、阳性对照的Ⅲ期临床研究。研究主要终点为52周时研究眼最佳矫正视力（BCVA）相较于基线的变化均值。彼时，荣昌生物方面披露称，除了DME适应证外，治疗湿性年龄相关性黄斑变性（wAMD）适应证预计2026年年中递交国内上市申请。　　去年8月，荣昌生物宣布将RC28-E大中华及亚洲区域的独家权益有偿许可给参天制药旗下全资子公司参天制药（中国）有限公司。（文章来源：中国经营报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655849376","isCrawlerRequest":true}